Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

Conditions are getting a bit more challenging for the drugmaker.

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company’s oral small molecule GLP1 drug ...

TORONTO - Canada’s main stock index moved lower Wednesday, weighed down by losses in base metals, while U.S. markets reversed earlier gains to end in the red. U.S. markets grappled with mixed ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

For TTY users: Use your preferred relay service or dial 711 then 988. Eli Lilly’s Kisunla is one of two drugs on the market aimed at slowing the progression of Alzheimer’s disease. But the ...